 |
| May
13, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Agios: Submits sNDA to FDA for U.S.
Accelerated Approval of Mitapivat in Sickle
Cell Disease More
- Charles River Laboratories and
MEDIPOST: Sign Non-Exclusive MOU
to Advance GMP Testing Solutions More
- Elpida Therapeutics and Catalent: Enter
Strategic Partnership for Late-Phase AAV
Manufacturing More
- EnPlusOne Biosciences: Significant
Advancements to its ezRNA Enzymatic RNA
Synthesis Platform and Introduces Novel
Modifications for Next-Generation RNA
Therapeutics More
- Enveric Biosciences: Expands IP Portfolio
With New U.S. Patent Issued for Methods of
Treating Psychiatric Disorders
More
- Kailera Therapeutics and Hengrui Pharma:
Clinical Data Presentations at the American
Diabetes Association 86th Scientific Sessions
More
- Liberate Bio: New Preclinical Data
Supporting First Clinical Evaluation of In
Vivo CAR-M Program LIB820 in Autoimmune
Disease More
- Moderna: Recognized by TIME as One of the
World’s Most Impactful Companies More
- Quanterix: Planned Transition of
Chief Financial Officer
More
- Renalytix and Carna Health: Partner to Solve
Kidney Disease Crisis: Bridging the Existing
Gap Between Population Screening and Precision
Intervention More
- Revvity: Receives FDA Clearance for Total
Testosterone Assay Enabling Comprehensive
Automated Testosterone Testing Solution More
- Veristat: Launches AI Biostatistics
Platform, Cutting Clinical Trial Data Readout
Time From 5 Weeks to 5 Days* Without
Regulatory Risks More
- Zenas BioPharma: First Subject Dosed in
Phase 1 Clinical Trial of ZB021, a Novel,
Potentially Best-in-Class Oral IL-17AA/AF
Inhibitor More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- Atea Pharmaceuticals: First Quarter 2026
Financial Results and Business Update
More
- Boehringer Ingelheim: Licenses Preclinical
Antibody Program From Immunitas Therapeutics
to Advance Treatments for Chronic Inflammatory
Diseasee More
More*
- Cerevance: Completes Enrollment in
Pivotal Phase 3 Parkinson’s Disease Trial
and Closes Oversubscribed $20 Million Series
C to Extend Runway Into 2027 More
- Corbus Pharmaceuticals: Q1 2026 Financial
Results and a Corporate Update More
- Crescent Biopharma: Grants of Inducement
Awards More
- Curis: First Quarter 2026 Business Update More
- Damora Therapeutics: First Quarter 2026
Financial Results and Recent Corporate
Highlights
More
- Fortis Life Sciences: Awards 2026 AbNano VHH
Discovery Grant to Deliver Biosciences for
Targeted Drug Delivery Research More
- Fractyl Health: First Quarter 2026 Financial
Results and Business Updates
More
- PepGen: First Quarter 2026 Financial Results
and Recent Corporate Highlights
More
- Solid Biosciences: First Quarter 2026
Financial Results and Business Updates More
- Upstream Bio: First Quarter 2026 Financial
Results and Recent Business Highlights More
- Vyome: Strikes Deal With Impetis
Biosciences, Opening a ~$57B Market
Opportunity
More
- Werewolf Therapeutics Vacates
Watertown Headquarters as Cash Dwindles More*
- Zenas BioPharma: First Quarter 2026
Financial Results and Corporate Update
More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Cardiff Insights: Life
Sciences Intelligence for the Week
More
- CBSET Builds 110,000-Square-Foot Waltham
Facility to Triple Capacity, House Foreign
Biotechs More*
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- Natalie Holles’ Next Move After Third
Harmonic Shutdown; Mark Alles Passes the Torch
at ADC Biotech More*
- Telling Your Science Story to
Investors More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
